Chiesi unveils 430M investment to revitalize Italian production site for inhaler, biologics manufacturing
Chiesi Group has announced a strategic €430 million investment to acquire and revitalize a manufacturing site in Nerviano, near Milan, Italy8. This investment, planned from 2025 to 2030, aims to transform a 124,000-square-meter industrial area into an international center of excellence for inhaler and biologics production8.
Key details of the investment include:
- Redevelopment of an existing site built in the 1980s into a next-generation production center8
- Over 3,000 square meters of laboratory space
- A photovoltaic park to ensure energy self-sufficiency
- Regeneration of a 20,000-square-meter wooded area adjacent to the facility8
The new site is expected to create approximately 300 new jobs by 2029, stimulating economic growth in the region8. This initiative is part of Chiesi's global industrial strategy, which includes ongoing investments in facilities in Parma (Italy), Blois (France), and Santana de Parnaíba (Brazil)8.
Giuseppe Accogli, CEO of Chiesi Group, stated that Nerviano was chosen for its strategic location and the potential of the industrial area8. This investment strengthens Chiesi's presence in Italy and Europe, consolidates its leadership in the sector, and complements recent investments such as the Biotech Center launch in Parma8.
The investment aligns with Chiesi's commitment to sustainability and innovation, supporting the company's goal of achieving Net Zero emissions by 20358.